Spruce Biosciences Valuation
| SPRB Stock | USD 0.55 0.02 3.77% |
Spruce Biosciences is undervalued. Spruce Biosciences has a current Real Value of $2.51 per share. The regular price of the company is $0.55. Our model measures the value of Spruce Biosciences from inspecting the company fundamentals such as Current Valuation of (34.94 M), shares owned by insiders of 10.50 %, and Return On Equity of -0.58 as well as reviewing its technical indicators and probability of bankruptcy. Key fundamental drivers impacting Spruce Biosciences' valuation include:
Price Book 0.4238 | Enterprise Value -34.9 M | Enterprise Value Ebitda (0.23) | Price Sales 3.0816 | Enterprise Value Revenue 15.3227 |
Undervalued
Today
Please note that Spruce Biosciences' price fluctuation is risky at this time. Calculation of the real value of Spruce Biosciences is based on 3 months time horizon. Increasing Spruce Biosciences' time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since Spruce Biosciences is currently traded on the exchange, buyers and sellers on that exchange determine the market value of Spruce Stock. However, Spruce Biosciences' intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 0.55 | Real 2.51 | Target 8.5 | Hype 0.53 | Naive 0.56 |
The real value of Spruce Stock, also known as its intrinsic value, is the underlying worth of Spruce Biosciences Company, which is reflected in its stock price. It is based on Spruce Biosciences' financial performance, growth prospects, management team, or industry conditions. The intrinsic value of Spruce Biosciences' stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, or news.
Estimating the potential upside or downside of Spruce Biosciences helps investors to forecast how Spruce stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of Spruce Biosciences more accurately as focusing exclusively on Spruce Biosciences' fundamentals will not take into account other important factors: Traditionally, analysts and sophisticated investors use multiple methods for valuing a cash-flow-generating entity or its stock. For example, some money managers use Spruce Biosciences' intrinsic value based on its ongoing forecasts of Spruce Biosciences' financial statements. In contrast, other private, professional wealth advisors use a multiplier approach by looking to relative value analysis against Spruce Biosciences' closest peers. If more than one evaluation category is relevant for Spruce Biosciences we suggest using both methods to arrive at a better estimate.
Spruce Biosciences Cash |
|
Spruce Valuation Trend
Comparing Spruce Biosciences' enterprise value against its market capitalization is a good way to estimate the value of Spruce Biosciences uage its performance over time. This information may sometimes be enough for investors to make reasonable market timing decisions.
Spruce Biosciences Total Value Analysis
Spruce Biosciences is at this time projected to have valuation of (34.94 M) with market capitalization of 21.88 M, debt of 4.61 M, and cash on hands of 93.3 M. The negative valuation of Spruce Biosciences may imply that the market is not capable to price the future growth of the company or it is pricing it at zero value. It may also suggest that takeover valuation may not have captured all of the outstanding financial obligations of the company both on and off balance sheet. Investors should vigilantly validate all of the Spruce Biosciences fundamentals.| Takeover Price | Market Cap | Debt Obligations | Cash |
(34.94 M) | 21.88 M | 4.61 M | 93.3 M |
Spruce Biosciences Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Spruce Biosciences has an asset utilization ratio of 9.71 percent. This suggests that the Company is making $0.0971 for each dollar of assets. An increasing asset utilization means that Spruce Biosciences is more efficient with each dollar of assets it utilizes for everyday operations.Spruce Biosciences Ownership Allocation
Spruce Biosciences shows a total of 41.3 Million outstanding shares. 30% of Spruce Biosciences outstanding shares are owned by institutional holders. Institutional investors are typically referred to investors that purchase positions in a given stock to benefit from reduced commissions. Consequently, institutional investors are subject to different rules and regulations than regular investors. Please look out for any change in current institutional holding as this could mean something significant has changed at the company or is about to change. Please note that no matter how many assets the company owns, if the real value of the company is less than the current market value, you may not be able to make money on it.Spruce Biosciences Profitability Analysis
The company reported the previous year's revenue of 10.09 M. Net Loss for the year was (47.92 M) with profit before overhead, payroll, taxes, and interest of 0.Please note that valuation analysis is one of the essential comprehensive assessments in business. It evaluates Spruce Biosciences' worth, which you can determine by considering its current assets, liabilities and future cash flows. The investors' valuation analysis is an important metric that will give you a perspective on different companies. It helps you know the worth of the potential investment in Spruce Biosciences and how it compares across the competition.
About Spruce Biosciences Valuation
The stock valuation mechanism determines Spruce Biosciences' current worth on a weekly basis. Our valuation model uses a comparative analysis of Spruce Biosciences. We calculate exposure to Spruce Biosciences's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of Spruce Biosciences's related companies.| Last Reported | Projected for Next Year | ||
| Gross Profit | -39.3 M | -37.4 M | |
| Pretax Profit Margin | (4.27) | (4.49) | |
| Operating Profit Margin | (4.64) | (4.87) | |
| Net Loss | (4.27) | (4.49) | |
| Gross Profit Margin | (3.51) | (3.69) |
Spruce Biosciences Growth Indicators
Growth stocks usually refer to those companies expected to grow sales and earnings faster than the market average. Growth stocks typically don't pay dividends, often look expensive, and usually trading at a high P/E ratio. Nevertheless, such valuations could be relatively cheap if the company continues to grow, which will drive the share price up. However, since most investors are paying a high price for a growth stock, based on expectations, if those expectations are not fully realized, growth stocks can see dramatic declines.
| Common Stock Shares Outstanding | 38.5 M |
Spruce Biosciences Current Valuation Indicators
Valuation refers to the process of determining the present value of Spruce Biosciences and all of its assets. It can be calculated using a number of techniques. As many analysts who try to value Spruce we look at many different elements of the entity such as Spruce's management, its prospective future earnings, the current market value of the company's assets, as well as its capital structure formation.
Valuations are an essential part of business, for companies themselves, but also for investors. For companies, such as Spruce Biosciences, valuations can help measure their progress and success and can help them track their performance in the market compared to others. In addition, investors can use Spruce Biosciences' valuations to help determine the worth of potential investments. They can do this by using data and information made public by a company. Regardless of who the valuation is for, it essentially describes Spruce Biosciences' worth.Complementary Tools for Spruce Stock analysis
When running Spruce Biosciences' price analysis, check to measure Spruce Biosciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Spruce Biosciences is operating at the current time. Most of Spruce Biosciences' value examination focuses on studying past and present price action to predict the probability of Spruce Biosciences' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Spruce Biosciences' price. Additionally, you may evaluate how the addition of Spruce Biosciences to your portfolios can decrease your overall portfolio volatility.
| Performance Analysis Check effects of mean-variance optimization against your current asset allocation | |
| Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
| Global Markets Map Get a quick overview of global market snapshot using zoomable world map. Drill down to check world indexes | |
| Funds Screener Find actively-traded funds from around the world traded on over 30 global exchanges | |
| Price Ceiling Movement Calculate and plot Price Ceiling Movement for different equity instruments | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Positions Ratings Determine portfolio positions ratings based on digital equity recommendations. Macroaxis instant position ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Sync Your Broker Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors. |